1. Home
  2. URGN vs DAO Comparison

URGN vs DAO Comparison

Compare URGN & DAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • URGN
  • DAO
  • Stock Information
  • Founded
  • URGN 2004
  • DAO 2006
  • Country
  • URGN United States
  • DAO China
  • Employees
  • URGN N/A
  • DAO N/A
  • Industry
  • URGN Biotechnology: Pharmaceutical Preparations
  • DAO Other Consumer Services
  • Sector
  • URGN Health Care
  • DAO Real Estate
  • Exchange
  • URGN Nasdaq
  • DAO Nasdaq
  • Market Cap
  • URGN 547.1M
  • DAO 623.9M
  • IPO Year
  • URGN 2017
  • DAO 2019
  • Fundamental
  • Price
  • URGN $12.84
  • DAO $4.58
  • Analyst Decision
  • URGN Strong Buy
  • DAO
  • Analyst Count
  • URGN 5
  • DAO 0
  • Target Price
  • URGN $44.50
  • DAO N/A
  • AVG Volume (30 Days)
  • URGN 764.9K
  • DAO 228.9K
  • Earning Date
  • URGN 11-12-2024
  • DAO 11-14-2024
  • Dividend Yield
  • URGN N/A
  • DAO N/A
  • EPS Growth
  • URGN N/A
  • DAO N/A
  • EPS
  • URGN N/A
  • DAO N/A
  • Revenue
  • URGN $85,011,000.00
  • DAO $788,903,658.00
  • Revenue This Year
  • URGN $16.49
  • DAO $11.06
  • Revenue Next Year
  • URGN $57.58
  • DAO $13.13
  • P/E Ratio
  • URGN N/A
  • DAO N/A
  • Revenue Growth
  • URGN 17.22
  • DAO 9.69
  • 52 Week Low
  • URGN $10.60
  • DAO $2.86
  • 52 Week High
  • URGN $20.70
  • DAO $5.97
  • Technical
  • Relative Strength Index (RSI)
  • URGN 49.60
  • DAO 53.54
  • Support Level
  • URGN $11.84
  • DAO $4.21
  • Resistance Level
  • URGN $13.54
  • DAO $5.07
  • Average True Range (ATR)
  • URGN 0.82
  • DAO 0.57
  • MACD
  • URGN 0.08
  • DAO -0.07
  • Stochastic Oscillator
  • URGN 65.88
  • DAO 28.72

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About DAO Youdao Inc. each representing one

Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and Youdao Pocket Translator.

Share on Social Networks: